2025

Medicines Australia’s HTA Policy Roundtable Report

2024

2024 Horizon Scanning Forum Report

2023

Medicines of Tomorrow >>> Australia’s First Horizon Scanning Forum

HTAnalysts whitepaper: HTA Summit held in November 2022

Funding Innovative Medicines whitepaper

Funding Innovative Medicines whitepaper summary

The Lichtenberg Report: From Hospital Beds to Healthy Lives

Medicines Manufacturing & Supply Chain is Robust and Complex

White Paper on Patent Notification

2022

Australia’s high discount rate is ignoring the health of our future generations

2021

Reviewing the National Medicines Policy – An opportunity to aim high for the future

2020

The Evolving Role of Real-world Evidence in Australia – Oncology Industry Taskforce November 2020

Medical Technology, Biotechnology, Pharmaceutical and Digital Health (MTP) Workplace Skills Report

Navigating (Compassionate) Access to Medicines For Trials Learnings from Industry to aid the Zero Childhood Cancer Trial and Recommendations arising from Industry / PRISM engagement

2019

The Impact Of Pharmaceutical Innovation On Premature Mortality And Hospitalisation In Australia, 1998-2018 by Professor Frank R. Lichtenberg

Economic footprint of the innovative pharmaceutical industry

Pharmaceutical Innovation flyer

2018

The Impact of ill health on retirement savings in Australia – full report

2017

Final report of an assessment of access to cancer medicines undertaken by Deloitte Access Economics

COMPARE

COMPARE (Comparison of Access and Reimbursement Environments): A report benchmarking Australia’s access to new medicines – Edition 5

COMPARE (Comparison of Access and Reimbursement Environments): A report benchmarking Australia’s access to new medicines – Edition 4 

COMPARE (Comparison of Access and Reimbursement Environments): A report benchmarking Australia’s access to new medicines – Edition 3 

COMPARE (Comparison of Access and Reimbursement Environments): A report benchmarking Australia’s access to new medicines – Edition 2

COMPARE (Comparison of Access and Reimbursement Environments): A report benchmarking Australia’s access to new medicines – Edition 1 

Please note, COMPARE has been revised with an minor update to Tables 1 and 2. These changes do not affect Australia’s ranking.